Sargramostim (Leukine)

DRUG8 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Crohn DiseaseCrohn's DiseaseLymphoma, Follicular

Phase 1

Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease

TerminatedNCT00206661

Genzyme, a Sanofi CompanyCrohn Disease

Start: 2004-12-31End: 2006-12-31Updated: 2013-12-04

Phase 2

Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease

CompletedNCT00206596

Genzyme, a Sanofi CompanyCrohn Disease

Start: 2003-07-31End: 2005-10-31Updated: 2013-12-04

Open-label Trial of Leukine in Active Crohn's Disease

TerminatedNCT00206700

Genzyme, a Sanofi CompanyCrohn Disease

Start: 2003-02-28End: 2006-12-31Updated: 2013-12-04

Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma

TerminatedNCT00308087

Genzyme, a Sanofi CompanyLymphoma, Follicular

Start: 2006-05-31End: 2009-06-30Updated: 2013-12-27

Study of Sargramostim in Moderately to Severely Active Crohn's Disease

TerminatedNCT00329537

Genzyme, a Sanofi CompanyCrohn's Disease

Start: 2006-06-30End: 2007-05-31Updated: 2013-12-04

Phase 3

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

CompletedNCT00206674

Genzyme, a Sanofi CompanyCrohn Disease

Start: 2004-09-30End: 2006-06-30Updated: 2013-12-04

Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim

TerminatedNCT00206713

Genzyme, a Sanofi CompanyCrohn Disease

Start: 2004-07-31End: 2006-10-31Updated: 2013-12-04

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

TerminatedNCT00295165

Genzyme, a Sanofi CompanyCrohn Disease

Start: 2006-01-31End: 2006-10-31Updated: 2013-12-04